FDA Approves Crizotinib for Treatment of ALK+ Inflammatory Advanced Myofibroblastic Tumors


Patients with ALK-positive inflammatory myofibroblastic tumors can now receive treatment with crizotinib following the agent’s approval by the FDA.

Crizotinib (Xalkori) has received approval from the FDA for the treatment of patients with unresectable, recurrent, or refractory ALK-positive inflammatory myofibroblastic tumors who are 1 year of age or older, according to a press release from the FDA.

The agent was evaluated in multiple clinical trials, including the phase 1/2 ADVL912 trial (NCT00939770) in a younger population of patients with relapsed/refractory solid tumors or anaplastic large cell lymphoma (n = 14), as well as the phase 1 A8081013 trial (NCT01121588) in adult patients solid ALK-positive malignancies with the exception of non–small cell lung cancer (n = 7). The oral drug can be administered at a recommended dose of 250 mg twice daily in adults and 280 mg/m2 twice daily in pediatric patients until progression or unacceptable toxicity.

The overall response rate was 86% (95% CI, 57%-98%) in the ADVL912 trial, with 5 of 7 patients in the A8081013 trial experiencing objective responses. Common adverse effects (AEs) in the pediatric population included vomiting, nausea, diarrhea, abdominal pain, rash, vision disorder, upper respiratory tract infection, cough, pyrexia, musculoskeletal pain, fatigue, edema, constipation, and headache, with common AEs in the adult population consisting of vision disorders, nausea, and edema.


FDA approves crizotinib for ALK-positive inflammatory myofibroblastic tumor. News release. FDA. July 14, 2022. Accessed July 14, 2022. https://bit.ly/3o10Eij

Related Videos
Implementing tax benefits for manufacturers who produce chemotherapy drugs may be one solution to increase drug production in the United States, according to Lucio N. Gordan, MD.
Lucio N. Gordan, MD, describes how his practice deals with increasing costs of limited chemotherapy agents to ensure that patients with cancer continue to receive treatment.
Lucio N. Gordan, MD, also discusses how increasing domestic manufacturing of chemotherapy may help in alleviating the ongoing shortages of carboplatin and cisplatin in the United States.
Kirollos Hanna, PharmD, BCPS, BCOP, FACCC, believes that national legislation can help to resolve the United States’ current dearth of cisplatin, as well as prevent future problems.
Using an AUC of 5 instead of an AUC of 6 can help to conserve cisplatin among patients with cancer, Kirollos Hanna, PharmD, BCPS, BCOP, FACCC says.
While there is a cisplatin shortage in the United States, the FDA has approved the importation of select chemotherapy drugs from China to help mitigate the scarcity of the agents.
Recommendations penned by the American Society of Clinical Oncology and Society for Gynecologic Oncology may be critical in managing the ongoing chemotherapy shortage, according to Michael Ganio, PharmD, MS, BCPS, FASHP.
Chemotherapy agents imported from Chinese manufacturers may have barcodes that don’t work or be missing an NDC number, according to Michael Ganio, PharmD, MS, BCPS, FASHP.
Results of a survey from the National Comprehensive Cancer Network indicate that almost all responding institutions are experiencing a carboplatin shortage.
Although opioid use guidelines from the Centers for Disease Control exclude patients with cancer, drug screenings are required that could further contribute to racial disparities.
Related Content